Epstein and Margolis bring decades of business expertise and industry leadership to Cancer Focus Fund as it prepares for Its next round of investments.
First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Promising early signals of activity seen as Phase 1 dose escalation proceeds
KAHR Bio reported topline results from a Phase 2a dose-expansion cohort evaluating its investigational immunotherapy DSP107 with Roche’s atezolizumab (Tecentriq) in late-line metastatic microsatellite stable colorectal cancer (MSS-CRC).
Biomed Israel 2026 and 8400 The Health Network announced Starget Pharma, caVos Biotech, Protai, and BAIBYS as winners of a startup showcase and competition for life sciences companies.
Investment accelerates AI-enabled radioligand discovery and clinical development, expands U.S. operations, and advances Louisiana's life sciences innovation ecosystem
Cancer Focus Fund is an oncology-focused investment firm advancing breakthrough cancer therapies by partnering with leading scientists, institutions and early-stage companies.
